Pipeline: Presbyopia treatment to finish Phase 3 late 2021

June 4, 2021

By Elad Kedar
Gretchyn M. Bailey, NCLC, FAAO, Editor in Chief, Content Channel Director

Video

Orasis Pharmaceuticals drop in development for treating presbyopia

Orasis Pharmaceuticals CEO Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Subscribe Now!

Recent Videos

Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz

Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.

Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.

Do not sell my Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Pipeline: Presbyopia treatment to finish Phase 3 late 2021

Newsletter